NN8640-4515 A multi-national, multi-centre, prospective, single-arm, observational, non-interventional post-authorisation safety study to investigate long-term safety of Sogroya® (somapacitan) in adults with growth hormone deficiency (AGHD) under routine clinical practice

Documents

Study protocol

Initial protocol

4515 16-1-01 protocol eu-pas-reg-redacted

Study results

Study report

Study report

4515 regulatory pass progress report no. 1 eu-pas-reg redacted

Other information

Study, other information

4515 regulatory pass progress report no. 2 eu-pas-reg redacted.pdf

4515 Regulatory Progress Report PASS Progress Report No 3.pdf